Dec 7 2009
The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical software solutions that help improve imaging workflow and productivity, and PenRad Technologies, Inc. ("PenRad"), a leader in the development of mammography information systems (MIS) are pleased to announce the first installation of the new PenLink connectivity package at Zwanger-Pesiri Radiology, Long Island's largest private medical imaging practice. This PenLink installation will be the first center in the world to integrate the benefits of automated ultrasound reporting from B-CAD with the PenRad comprehensive MIS required to maintain state of the art quality control for Breast Imaging. Medipattern announced their collaboration with PenRad in a press release dated November 26, 2009. The first products resulting from the collaboration are PenLink and PenView. PenLink reads the information from the B-CAD breast ultrasound report and automatically enters the CAD results into PenRad Technologies' PenRadTM Reporting System, dramatically improving clinical and reporting workflow.
"Having B-CAD directly feed PenRad is a phenomenal jump in productivity and simplifies workflow. The CAD results are automatically populated directly into the radiologist report. The radiologist can then review images, CAD findings, edit and document the case," commented Steven Mendelsohn, MD medical director and co-owner of Zwanger-Pesiri. "This saves time on every breast ultrasound exam, while increasing consistency and accuracy with B-CAD."
Zwanger-Pesiri provides state of the art services to the communities of Nassau and Suffolk Counties in New York in eight locations. Zwanger-Pesiri was founded in 1953 with the purpose of providing referring physicians and patients on Long Island with modern medical diagnostics. The practice was the first in the area to offer specialized imaging with a 3 Tesla MRI, first with 128 slice CT following on in the tradition of providing leading edge, innovative medicine to better care for the community.
"This is the first of a series of products designed to combine the power of CAD with broad based MIS clinical reporting. All of these products define a new level of integration that is made possible through our collaborative agreement," added Jeff Collins, President and CEO of The Medipattern Corporation. "We are pleased that our efforts with PenRad have generated an immediate response. We would also like to congratulate our reseller Amy Eriksen of Physicians Consultant Medical Sales of New York for facilitating this transaction."
Source The Medipattern Corporation
AI and imaging technologies transform pancreatic cancer diagnostics